CD62L levels are thought to be predictive of treatment response in leukemia37 and risk of adverse events in multiple sclerosis therapy38; the effect of the L-selectin eQTL on protein levels could thus be misconstrued in a clinical setting. The gene discussed is SELL; the disease is multiple sclerosis.